AbbVie Bets $11B on Apogee's Autoimmune Pipeline

Good morning, healthcare professional.

The pharmaceutical industry is making major moves today, with AbbVie announcing an $11 billion acquisition of Apogee Therapeutics while China greenlights a historic CAR-T therapy for solid tumors. Meanwhile, Eli Lilly escalates its battle with hospitals over drug discount programs, and the FDA backtracks on another gene therapy rejection.

These stories reflect broader shifts in biopharma strategy, regulatory flexibility, and the ongoing tension over drug pricing. From breakthrough science to billion-dollar deals, today's developments will shape treatment access and industry dynamics for years to come.

In today's healthcare digest:

• AbbVie stakes nearly $11 billion on long-acting autoimmune drugs
• CARsgen wins world's first CAR-T approval for solid tumors
• Eli Lilly terminates 340B discounts over hospital data disputes
• FDA reverses rejection of Regenxbio's pediatric gene therapy

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in M&A Boom

AbbVie announced plans to acquire Apogee Therapeutics for approximately $11 billion, securing access to experimental long-acting antibodies for autoimmune diseases including eczema. The deal exemplifies the accelerating M&A activity across the pharmaceutical sector, with 2026 transactions already totaling $123 billion.

Unpacked:

• The acquisition centers on zumilokibart, an investigational IL-13 blocker currently in Phase 2 trials for atopic dermatitis.
• AbbVie faces looming patent expirations on blockbuster drugs, making pipeline expansion through acquisitions strategically critical.
• This marks the latest in a series of major pharma deals as companies rush to replenish pipelines.

CARsgen Makes History with World's First CAR-T Approval for Solid Tumors

China's National Medical Products Administration approved CARsgen's CAR-T therapy for gastric cancer, marking the first time any regulatory agency has authorized a CAR-T treatment for solid tumors. The approval represents a major scientific breakthrough after years of failed attempts to extend CAR-T success beyond blood cancers.

Unpacked:

• CAR-T therapies have shown remarkable results in leukemia and lymphoma but struggled against solid tumors until now.
• The approval addresses gastric cancer, which remains a leading cause of cancer deaths in Asia.
• This milestone could accelerate development of CAR-T platforms targeting other solid tumor types globally.

Eli Lilly Ends 340B Drug Discounts to Hospitals Over Data Dispute

Eli Lilly followed through on its ultimatum to terminate 340B drug discounts for hospitals that failed to provide claims data, escalating a contentious dispute over the federal drug discount program. The move affects hospitals serving low-income and uninsured patients who rely on 340B savings to fund care.

Unpacked:

• The 340B program requires drugmakers to provide discounts to qualifying hospitals but lacks transparency requirements.
• Lilly argues it needs claims data to prevent duplicate discounts and ensure drugs reach intended patients.
• Hospital groups warn the action will reduce their ability to provide charity care and community health services.

FDA Reverses Course on Regenxbio Gene Therapy After Initial Rejection

The FDA reversed its rejection of Regenxbio's gene therapy for Hunter syndrome, a rare pediatric metabolic disorder, allowing the company to resubmit its application. The reversal continues a pattern of FDA policy shifts on gene therapies following initial negative decisions.

Unpacked:

• Hunter syndrome causes progressive organ damage in children, with limited treatment options currently available.
• The FDA initially rejected the therapy but later indicated the application could be resubmitted with clarifications.
• This marks another instance where FDA has walked back gene therapy rejections after industry and patient advocacy.

The Shortlist

• Biogen announced a $1 billion acquisition of secretive startup Raythera to expand its immunology pipeline with undisclosed experimental therapies.

• Pfizer's CFO will step down following disappointing clinical trial results for its lung cancer antibody-drug conjugate sigvotatug vedotin.

• Sanofi appointed a new R&D chief as the company attempts to revitalize a pipeline that has lagged competitors in recent years.

• Bionyra raised $165 million in Series A funding to develop next-generation immune system modulators for autoimmune conditions.

• Definium reported positive Phase 3 trial results for its LSD-based therapy treating major depressive disorder in treatment-resistant patients.